AGA2115

DRUG4 trials

Sponsors

Angitia Inc. Ltd., Angitia Incorporated Limited, Angitia Biopharmaceuticals Guangzhou Limited

Conditions

Osteogenesis ImperfectaOsteogenesis Imperfecta (OI)

Phase 1

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

CompletedNCT06086613

Angitia Incorporated LimitedOsteogenesis Imperfecta

Start: 2023-10-03End: 2024-10-17Updated: 2025-01-10

Phase 2

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

RecruitingNCT07062588

Angitia Incorporated LimitedOsteogenesis Imperfecta (OI)

Start: 2025-12-12End: 2029-02-01Target: 80Updated: 2026-08-17

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

RecruitingNCT07557446

Angitia Biopharmaceuticals Guangzhou LimitedOsteogenesis Imperfecta (OI)

Start: 2026-06-01End: 2029-07-01Target: 48Updated: 2026-06-22

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Not yet recruitingCTIS2025-522951-24-00

Angitia Inc. Ltd.Osteogenesis Imperfecta

Target: 15Updated: 2026-06-22